Innovent Biologics Inc
HKEX:1801
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
30.1
51.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Innovent Biologics Inc
Innovent Biologics Inc
Gross Profit
Innovent Biologics Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovent Biologics Inc
HKEX:1801
|
Gross Profit
¥6.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Gross Profit
¥14.7B
|
CAGR 3-Years
108%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Gross Profit
¥4.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
335%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Gross Profit
¥4.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Gross Profit
¥9.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
34%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Gross Profit
¥2.7B
|
CAGR 3-Years
61%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
Glance View
In the bustling landscape of the biotechnology industry, Innovent Biologics Inc. stands out as a dynamic player committed to advancing precision medicine. Founded in 2011, this Chinese-based company has carved out a significant niche in the development of monoclonal antibodies for oncology, metabolic disorders, and autoimmune diseases. Innovent sought to bridge the gap between innovation and affordability, an ambitious vision fueled by strategic collaborations with global pharma giants and local research centers. The company’s flagship product, Tyvyt (sintilimab), is a testament to their pioneering spirit—a PD-1 inhibitor developed in partnership with Eli Lilly, which gained approval for the treatment of various cancers in China. Innovent leverages its robust in-house R&D capabilities and partnerships to craft an extensive pipeline of potential therapies, positioning itself as a linchpin in the race to address unmet medical needs across its target markets. Innovent Biologics generates revenue through strategic licensing agreements, collaborative development programs, and direct sales of its commercialized therapies. It adopts a multinational partnership model that allows it to both share development costs and tap into broader distribution channels, thus accelerating growth while minimizing financial risk. By focusing on biopharmaceuticals that address prevalent health concerns, Innovent capitalizes on the rising demand for innovative healthcare solutions in China and beyond. Furthermore, the company's vertically integrated infrastructure—from research to commercialization—ensures optimized costs and sustained profitability in a competitive industry landscape. Innovent’s financial trajectory is buoyed by its ability to balance cutting-edge scientific innovation with strategic market positioning, underscoring its reputation as a formidable force in global biotech.
See Also
What is Innovent Biologics Inc's Gross Profit?
Gross Profit
6.1B
CNY
Based on the financial report for Jun 30, 2024, Innovent Biologics Inc's Gross Profit amounts to 6.1B CNY.
What is Innovent Biologics Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
82%
Over the last year, the Gross Profit growth was 52%. The average annual Gross Profit growth rates for Innovent Biologics Inc have been 12% over the past three years , 82% over the past five years .
You don't have any saved screeners yet
